Business Context and Reporting Period
Company: electroCore, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 28, 2018
Reporting Period: Single event date (November 28, 2018)
Business Context: The registrant is an emerging growth company focused on non-invasive vagus nerve stimulator (nVNS) therapy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
Regulatory Milestone: On November 28, 2018, the company announced FDA clearance for its gammaCore® therapy.
Indication: Adjunctive use for the preventive treatment of cluster headache in adults.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) detailing the FDA clearance but does not include specific forward-looking guidance, financial outlook, or risk factors within the text of this 8-K.
Unusual Items: None reported beyond the regulatory approval event.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for specific commercialization plans.
- Confirm the scope of the FDA clearance regarding "adjunctive use" and patient eligibility.
- Review subsequent filings for any financial impact or revenue recognition related to this new indication.
- Check the company's status as an emerging growth company for potential reporting exemptions.